Figure 1.

CDK9 is highly expressed in human ovarian cancer and is associated with invasive progression. A. Representative images of nuclear staining intensity for CDK9 in 7 normal ovary samples and 12 early-stage (stage I or II) and 21 advanced-stage (stage III or IV) ovarian high-grade serous adenocarcinoma samples. The stage of ovarian cancer was defined based on the International Federation of Gynecology and Obstetrics (FIGO) staging system. Scale bar, 200 μm. B. IHC scores for CDK9 in ovarian tumor tissues and normal ovarian tissues. ANOVA with the post hoc test. C. Comparison of the CDK9 protein levels in ovarian tumors and normal ovarian tissues by Western blot analysis. Tubulin was used as a loading control. D, E. The progression-free survival (PFS) and overall survival (OS) rates in the high-CDK9 and low-CDK9 groups of ovarian cancer patients by Kaplan-Meier plotter analysis (http://kmplot.com/analysis).